Professor Shahina Pardhan has been appointed director of Anglia Ruskin University's new Vision and Eye Research Unit (VERU).
Professor Shahina Pardhan has been appointed director of Anglia Ruskin University’s new Vision and Eye Research Unit (VERU).
Professor Pardhan has an extensive background in optometry and research based on the clinical assessment of visual functions in range of normal and abnormal ocular conditions including myopia, low vision and normal vision. She was the first woman to become Professor of Optometry at Anglia Ruskin University and has been awarded the Asian Jewel Award (Health care and education category) and the Asian Women of Achievement award.
Talking to the Cambridge Network she said: "I am really looking forward to this exciting new venture and working with vision and eye researchers both within Anglia Ruskin and externally. We have an outstanding team here, offering world-leading expertise which is already proving attractive to organisations seeking to fulfil their research and development needs."
VERU will build on existing collaborations and build new research partnerships both in- and outside the university, including the NHS and partners in the optical and pharmaceutical industries. Other experts involved with the unit include Professor Rupert Bourne, Professor of Ophthalmology at Anglia Ruskin, Professor Roger Buckley, Professor of Ocular Medicine at Anglia Ruskin and Dr Sarah Waugh, Reader in the Department of Optometry and Ophthalmic dispensing at Anglia Ruskin.
AAO 2024: Transient vision loss with Alexander Fein, MD
October 21st 2024Alexander Fein, MD, spoke with the Eye Care Network to share how to approach a patient presenting with transient vision loss, what this type of vision loss can mean, and what additional testing might be needed to determine the best plan for care.
AAO 2024: Optimal pupil size reduction percentage for near vision improvement in presbyopia
October 21st 2024Jennifer Loh, MD, shared insights from on her presentation at the American Academy of Ophthalmology meeting in Chicago on the effects of CSF-1, which is the lowest effective concentration of pilocarpine approved in the United States.